Compare Kimco Realty Corporation (HC) Common Stock (KIM) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kimco Realty Corporation (HC) Common Stock vs Organon & Co. Common Stock — how do they compare? Kimco Realty Corporation (HC) Common Stock trades at $22.48 (market cap $15.06B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Kimco Realty Corporation (HC) Common Stock is far larger — about 4.2× Organon & Co. Common Stock's market cap, and Kimco Realty Corporation (HC) Common Stock pays the higher dividend (4.99%). Which is the better fit depends on your goals — on Pluang, investors hold Kimco Realty Corporation (HC) Common Stock for 6 Days and Organon & Co. Common Stock for 0 Days on average.
| KIM | OGN | |
|---|---|---|
Market Cap | $15.06B | $3.62B |
Volume | 6,246,987 | 2,892,999 |
Sector | Real Estate | Health |
52-Week High | $26.38 | $13.81 |
52-Week Low | $19.78 | $5.70 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $23.22B | $11.04B |
Dividend Yield | 4.99% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KIM trades at $22.45, up 0.58% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results expected soon. Fundamentals show robust profitability with a 27.76% net income margin and a P/E of 26.1. Analyst consensus is a Buy with a $26.09 price target, though technical indicators suggest near-term caution.
The outlook for KIM is mixed; strong fundamentals and positive analyst sentiment support upside, but technical bearishness and macroeconomic risks pose challenges. Investment opportunity lies in its high dividend yield and earnings growth, while risks include market volatility and real estate sector headwinds. The stock's performance will hinge on upcoming earnings and broader economic conditions.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Kimco Realty Corporation (HC) Common Stock
Kimco Realty is a real estate investment trust that owns and operates open-air, grocery-anchored shopping centers and mixed-use properties in the United States.
Read more on KIM →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
